ASCO GI 2021 Archives - Medical Conferences

Home > Oncology > ASCO GI 2021

Read the full Report (pdf)

ASCO Gastrointestinal Cancers Symposium 15-17 January 2021

Featured articles

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ASCO GI 2021

12 March, 2021 11:15

ASCO GI 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2021

12 March, 2021 11:08

Online First

Oesophageal and Gastric Cancer

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

Presented By

Prof. Zev Wainberg, UCLA, USA

Trial

Phase 2, FIGHT

Conference

ASCO GI 2021

12 March, 2021 11:50

Gut microbiome DELIVERs nivolumab forecast in gastric cancer

Presented By

Prof. Yu Sunakawa, St Marianna University School of Medicine, Kanagawa, Japan

Trial

DELIVER

Conference

ASCO GI 2021

12 March, 2021 11:47

OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward

Presented By

Prof. Josep Tabernero, Vall d'Hebron Institute of Oncology, Spain

Trial

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By

Prof. Kazuo Koyanagi, National Cancer Center, Japan

Trial

Phase 3, JCOG 1109

Conference

ASCO GI 2021

12 March, 2021 11:42

Adjuvant nivolumab: good quality-of-life

Presented By

Prof. Eric Van Cutsem, University of Leuven, Belgium

Trial

Phase 3, CheckMate 577

Conference

ASCO GI 2021

12 March, 2021 11:40

Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse

Presented By

Prof. Kazuhiro Yoshida, Gifu University, Japan

Trial

Phase 2, JACCRO GC-07

Conference

ASCO GI 2021

12 March, 2021 11:38

Anal and Colorectal Cancer

First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC

Presented By

Dr Kai-Keen Shiu, University College London Hospitals NHS Foundation Trust, UK

Trial

Phase 3, KEYNOTE-177

Conference

ASCO GI 2021

12 March, 2021 11:52

Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients

Presented By

Dr Eric Francois, Centre Antoine-Lacassagne, France

Trial

PRODIGE 42-GERICO 12 NACRE

Conference

ASCO GI 2021

12 March, 2021 11:50

Circulating tumour DNA predicts recurrence in colorectal cancer

Presented By

Tenna Henriksen, Aarhus University, Denmark

Conference

ASCO GI 2021

12 March, 2021 11:48

Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results

Presented By

Dr Osama Rahma, Dana-Farber Cancer Institute, USA

Trial

Phase 2

Conference

ASCO GI 2021

12 March, 2021 11:46

Prognostic value of tumour deposits in stage 3 colon cancer patients

Presented By

Dr Romain Cohen, Mayo Clinic, USA

Trial

Phase 3, CALGB/SWOG 80702

Conference

ASCO GI 2021

12 March, 2021 11:43

Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC

Presented By

Dr Michael Lee, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO GI 2021

12 March, 2021 11:41

Preliminary surgery salvage data after watch & wait policy from OPERA trial

Trial

Phase 3, OPERA

Conference

ASCO GI 2021

12 March, 2021 11:40

Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers

Presented By

Prof. Thomas Seufferlein, University of Ulm, Germany

Trial

Phase 1/2, PERMAD

Conference

ASCO GI 2021

12 March, 2021 11:37

Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Presented By

Prof. Eric Van Cutsem, KU Leuven, Belgium

Trial

Phase 2, TASCO1

Conference

ASCO GI 2021

12 March, 2021 11:35

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC

Presented By

Dr Valérie Boige, Institut Gustave Roussy, France

Trial

Phase 2, PRODIGE 28-time UNICANCER

Conference

ASCO GI 2021

12 March, 2021 11:33

Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy

Presented By

Dr Jeffrey Chi, Northwell Health Cancer Institute, NY, USA

Conference

ASCO GI 2021

12 March, 2021 11:31

Hepatobiliary Cancer

Ivosidenib in second-line improves OS in IDH1-mutant cholangiocarcinoma

Presented By

Dr Andrew Zhu, Harvard Medical School, USA

Trial

Phase 3, ClarIDHy

Conference

ASCO GI 2021

12 March, 2021 11:46

Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma

Presented By

Prof. Milind Javle, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO GI 2021

12 March, 2021 11:42

Landmark OS for HCC, updated IMbrave150 data

Presented By

Prof. Richard Finn, UCLA, USA

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2021

12 March, 2021 11:39

Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC

Presented By

Prof. Philippe Merle, University Hospital Lyon, France

Trial

Phase 3, KEYNOTE-240

Conference

ASCO GI 2021

12 March, 2021 11:37

Phase 2 study supports first-line pembrolizumab in advanced HCC

Presented By

Dr Jean-Luc van Laethem, Hôpital Erasme–Université Libre de Bruxelles, Belgium

Trial

Phase 2, KEYNOTE-224

Conference

ASCO GI 2021

12 March, 2021 11:35

Yttrium-90 (Y-90) glass microspheres for HCC

Presented By

Prof. Robert Lewandowski, Northwestern University, Chicago, USA

Trial

LEGACY

Conference

ASCO GI 2021

12 March, 2021 11:33

Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation

Presented By

Prof. Masatoshi Kudo, Kindai University, Osaka, Japan

Trial

Phase 2, TACTICS

Conference

ASCO GI 2021

12 March, 2021 11:30

Zanidatamab provides ORR in HER2+ biliary tract cancer

Presented By

Prof. Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 1

Conference

ASCO GI 2021

12 March, 2021 11:28

Pancreatic Cancer

Borderline resectable pancreatic cancer: phase 2 results

Presented By

Prof. Matthew H. Katz, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2, Alliance A021501

Conference

ASCO GI 2021

12 March, 2021 11:12

No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer

Presented By

Prof. Talia Golan, Sheba Medical Center, Israel

Trial

Phase 3, POLO

Conference

ASCO GI 2021

12 March, 2021 11:02

Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV

Presented By

Prof. Kyunghye Bang, Asan Medical Center, Korea

Conference

11:05:57pm> from conference

12 March, 2021 10:59

Neuroendocrine Cancer

No benefit of adding axitinib to ocreotide acetate in non-pancreatic neuroendocrine tumours

Presented By

Dr Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, AXINET trial-GETNE-1107

Conference

ASCO GI 2021

12 March, 2021 10:44

Phase 2 abemaciclib trial in patients with advanced NETs

Presented By

Prof. Kaylyn Kit Man Wong, University of Washington, USA

Trial

Phase 2

Conference

ASCO GI 2021

12 March, 2021 10:39

COVID-19

COVID-19 impact on gastrointestinal cancer care

Presented By

Dr Nicholas Perkons, University of Pennsylvania, Philadelphia, USA)

Conference

ASCO GI 2021

12 March, 2021 10:59

Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS

Presented By

Dr Matthew Parsons, University of Utah, USA

Conference

ASCO GI 2021

12 March, 2021 10:58

Featured articles

CONTENTS

Online First

Oesophageal and Gastric Cancer

Anal and Colorectal Cancer

Hepatobiliary Cancer

Pancreatic Cancer

Neuroendocrine Cancer

COVID-19